Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEFRTZ)

• Drug Name: Lurbinectedin Drug Info
• Synonyms: UNII-2CN60TN6ZS; 497871-47-3; 2CN60TN6ZS; Lurbinectedin [INN]; SCHEMBL16152477; DTXSID30198065; DB12674; CS-6323; HY-16293; J3.652.626B

Indication

Disease Entry	ICD 11	Status	REF
Small-cell lung cancer	2C25.Y	Approved	[1]
leukaemia	2A60-2B33	Phase 3	[2]
Ovarian cancer	2C73	Phase 3	[2]
Endometrial cancer	2C76	Phase 2	[3]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]

• Cross-matching ID:
  PubChem CID: 57327016
  CAS Number: CAS 497871-47-3
  TTD Drug ID: DMEFRTZ
  ACDINA Drug ID: D01230

Molecule-Related Drug Atlas

Drug(s) Targeting Human Deoxyribonucleic acid minor groove (hDNA min)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brostallicin	DMUI5PA	Breast cancer	2C60-2C65	Phase 2	[4]
Di-imidazole lexitropsin	DME4NH1	Discovery agent	N.A.	Investigative	[5]
Duocarmycin	DM0CQIP	Discovery agent	N.A.	Investigative	[6]
Netropsin	DMOW2QS	Discovery agent	N.A.	Investigative	[7]
Distamycin A	DMPVNDK	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Human Deoxyribonucleic acid (hDNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[9]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[10]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[11]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[12]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[13]
Carboplatin	DMG281S	Adenocarcinoma	2D40	Approved	[14]
Busulfan	DMXYJ9C	Chronic myelogenous leukaemia	2A20.0	Approved	[15]
Procarbazine	DMIK367	Hodgkin lymphoma	2B30	Approved	[16]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[6]
Dacarbazine	DMNPZL4	Adenocarcinoma	2D40	Approved	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Inhibitor	[1]
Human Deoxyribonucleic acid minor groove (hDNA min)	TTOVXHF	NOUNIPROTAC	Inhibitor	[1]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] ClinicalTrials.gov (NCT02421588) Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity. Expert Opin Investig Drugs. 2009 Dec;18(12):1939-46.
• [5] Defining GC-specificity in the minor groove: side-by-side binding of the di-imidazole lexitropsin to C-A-T-G-G-C-C-A-T-G. Structure. 1997 Aug 15;5(8):1033-46.
• [6] Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
• [7] Drug-DNA binding specificity: binding of netropsin and distamycin to poly(d2NH2A-dT). Biopolymers. 1990;30(1-2):223-7.
• [8] Development of distamycin-related DNA binding anticancer drugs. Expert Opin Investig Drugs. 2001 Sep;10(9):1703-14.
• [9] Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
• [10] Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
• [11] 31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
• [12] Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
• [13] O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
• [14] Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
• [15] DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8.
• [16] Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
• [17] Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.